


Basic Results Update

Investigating the role of salt inducible kinases in atherosclerosis: ISRCTN14632677

Participant Flow



Baseline Characteristics

	Blood Flow and Inflammatory Biomarker Study		Amputation Study
<i>Group</i>	Healthy Controls (n=30)	STEMI (n=40)	PVD (n=20)
Age (years)	60.0 (SD 10.5)	59.4 (SD 10.4)	69.2 (SD 10.7)
Sex (% male)	63%	92.5%	85%
BMI (kg/m²)	24.3 (SD 3.2)	28.1 (SD 5.5)	25.74% (SD 3.9)
Blood Pressure (mmHg) Systolic Diastolic	127.2 (SD 14.8) 77.0 (SD 8.9)	117.0 (SD 14.8) 70.9 (SD 9.7)	141.0 (SD 19.4) 74.8 (SD 6.8)
Smokers (%)	7.1% smoker 78.6% non-smoker 14.3% ex-smoker	34% smoker 17.4% non-smoker 47.8% ex-smoker	50% smoker 50% ex-smoker (12 out 20 histories available)
Diabetes (%)	0%	17%	53.8% (13 out 20 histories available)
Diagnosed Hypertension (%)	0%	37.5%	83.3% (12 out 20 histories available)
Diagnosed Hypercholesterolemia (%)	0%	41.2%	16.7% (12 out 20 histories available)
Medications			
<i>Aspirin</i>	N/A	97.4%	63.2%
<i>Clopidogrel</i>	N/A	97.4%	42.1%
<i>Statins</i>	N/A	97.4%	73.7%
<i>ACE inhibitors/ARBs</i>	N/A	84.6%	36.8%
<i>B-Blockers</i>	N/A	89.7%	31.8%
<i>Anticoagulants</i>	N/A	12.8%	47.4%
<i>Calcium Channel Blockers</i>	N/A	10.3%	21.1%
<i>Diuretics</i>	N/A	20.5%	26.3%
<i>Neuropainkillers</i>	N/A	0%	57.9%

Outcome Measures

	Blood Flow and Inflammatory Biomarker Study		
<i>Group</i>	Healthy Controls (n=30)	STEMI (n=40)	<i>p</i> -value
Flow Mediated Dilation			
<i>Cuff Change %</i>	6.58	3.58	<0.0001*
<i>GTN Cuff Change %</i>	17.79	8.17	<0.0001*
Pulse Wave Analysis			
<i>AIx75%</i>	20.53	18.12	0.3457
<i>Carotid-Radial PWV (m/s)</i>	8.09	8.16	0.8113
Gene Expression within Peripheral Blood Mononuclear Cells (Fold Change)			
<i>SIK2</i>	1	1.13	0.3783
<i>SIK3</i>	1	0.70	0.0064*
<i>MSK1</i>	1	0.59	<0.001*
<i>MSK2</i>	1	0.70	<0.001*
<i>IL-10</i>	1	2.07	0.001*
Serum Cytokine Levels			
<i>IL-6 (ng/ml)</i>	0.85	6.55	<0.0001*
<i>IL-10 (pg/ml)</i>	5.15	9.52	0.002*

Analysis of the PVD arterial samples using immunohistochemistry is still underway results expected imminently.

Adverse Events

No adverse effects were observed with patients or controls during their visit and whilst under the study protocols.